Rho et al. [24] also observed reduced expression of EGFR, HER3, and MET and significantly enhanced activation of AKT in a gefitinib-resistant non-small-cell lung cancer cell line (A549) with EMT characteristics. This evidence concerns the gene MET and non-small cell lung carcinoma.